Drugs / ES009
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06007482 | Sep 2023 → Feb 2025 | neoplasm | Elpiscience Biopharma, Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-21 | Elpiscience Biopharma, Ltd. | Results Highlight Recap | Elpiscience Showcases Three Innovative Research Studies at SITC 2025, Demonstrating Original Innovation on the Global Academic Stage elpiscience.com ↗
ES009, a differentiated and potentially best-in-class LILRB2 inhibitor, demonstrating favorable safety, tolerability, PK/PD, and preliminary antitumor activity in a first-in-human Phase 1 study; |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-21 | Elpiscience Biopharma, Ltd. | Highlight Recap | Elpiscience Showcases Three Innovative Research Studies at SITC 2025, Demonstrating Original Innovation on the Global Academic Stage elpiscience.com ↗ |
| 2023-09-26 | Elpiscience Biopharma, Ltd. | Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of Anti-LILRB2 Antibody ES009 in Australia elpiscience.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ES009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06007482 ↗ |
| Action | Inhibit | “targets and blocks LILRB2” NCT06007482 ↗ |
| Modality | Monoclonal antibody | “ES009 is a recombinant humanized IgG4 monoclonal antibody” NCT06007482 ↗ |
| Route | Intravenous | “ES009 is administered via intravenous infusion” NCT06007482 ↗ |
| Target | LILRB2 | “specifically targets and blocks LILRB2” NCT06007482 ↗ |